Mirati Therapeutics

Mirati Therapeutics, Inc. is an American targeted oncology company that focuses on the development of cancer therapeutics.[1] Bristol Myers Squibb acquired the company in January 2024.

History

Mirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it.[2] The inhibition to the mutation has shown to shrink the size of its tumors.[3] The company is based in San Diego, California. The company’s name comes from the Italian word for “targeted” (Mirati). Mirati Therapeutics is traded on the Nasdaq[4] under the ticker symbol MRTX.[5] It joined the exchange in 2013.[6]

In October 2023, Bristol Myers Squibb agreed to acquire the company in an all-cash deal worth $4.8 billion, and an additional $1 billion in milestone payment.[7] The acquisition was completed in January 2024.[8]

Drug candidates

The company’s leading drug candidates are sitravatinib and adagrasib.[9] Mirati also has a preclinical candidate against the G12D mutation.[10]

Management

The company’s CEO and President is David Meek.[11]

External links